Law 360 M&A

FEBRUARY 14, 2024

Former stockholders of drug developer Paratek Pharmaceuticals Inc.

98

98

Benzinga

JUNE 27, 2023

BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. Paratek appreciates receiving constructive feedback from its stockholders and as such, has actively engaged with NexPoint over the past several months. About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc.

40

40

Benzinga

SEPTEMBER 12, 2023

The Glass Lewis recommendation follows the recent receipt of the recommendation from Institutional Shareholder Services Inc. ("ISS") Lead Independent Director of Paratek's board of directors (the "Board"). BOSTON, Sept. ISS") to vote FOR the transaction.

Marketability 45

Marketability 45

Benzinga

JUNE 6, 2023

Transaction Provides Paratek Shareholders with Immediate Value and Liquidity Reflects Potential Value of $3.00 June 06, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. Transaction Provides Paratek Shareholders with Immediate Value and Liquidity Reflects Potential Value of $3.00

Debt Financing 40

Debt Financing Finance Marketability 40

Benzinga

SEPTEMBER 21, 2023

21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings") announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. Chief Executive Officer at Paratek. "We CAMBRIDGE, Mass.,

40

40

Law 360 M&A

JUNE 6, 2023

Commercial-stage biopharmaceutical company Paratek Pharmaceuticals Inc. said Tuesday that it will become a private company after agreeing to a purchase by Gurnet Point Capital and Novo Holdings A/S in a deal valued at roughly $462 million and steered by three firms.

40

40

Law 360 M&A

JUNE 27, 2023

Activist investor NexPoint Asset Management LP on Tuesday revealed its plans to withhold votes against all three Paratek Pharmaceuticals Inc.

40

40